我国2003-2012年药物经济学评价文献计量分析

Bibliometric Analysis of Pharmacoeconomics Evaluation in China during 2003-2012

目的:了解药物经济学研究在我国发展的水平和现状,为加强研究的政策转化提供实证依据。方法:对我国作者2003-2012年在国内期刊发表的药物经济学评价有效文献2 619篇与在国际期刊发表的文献115篇进行文献计量分析,重点关注期刊和作者的分布、研究方法、资助和关注焦点的情况。结果:近十年药物经济学评价文献的数量有了大幅度提高,形成了学科和人才建设的规模,作者与期刊的地理分布相对分离;作者主要来自医院药剂部门和业务科室以及复旦大学、北京大学等高校;研究方法以成本效果分析和最小成本分析为主,成本效用和成本效益方法运用较少;研究对决策的支持作用尚难体现。结论:建议学习其他国家和地区的经验,建立制度性的支持研究和决策转化的框架,推动研究与卫生资源配置决策的互动,建立文章的分级质量标准体系,学科建设应重视发挥高校和教学医院各自的优势。

OBJECTIVE： To review the development and situation of pharmacoeconomics （PE） evaluation in China, and to provide empirical evidence for strengthening policy-translation research. METHODS： Bibliometric analysis was conducted among 2 619 literatures of PE in domestic journals and 115 literatures by domestic authors in international journals during 2003- 2012. Great importance should be attached to the distribution of journals and author, research method, sponsor and the focus of concern. RESULTS ： The number of PE literatures greatly increased in the past ten years, indicating the development of pharmacoeconomics discipline and the growth of a group of scholars. The authors and journals geographically relatively distributed separately. The author group mainly comprised those from pharmacy and clinical department of hospitals and from universities, such as Fudan University and Peking University. Most studies applied methods of CEA and CMA, while CBA and CUA were seldom used. The connection between research findings and policy making was not transformed. CONCLUSIONS： It is suggested that international experience from other countries should be learned to institutionalize the policy framework and encourage the interaction between researchers and decision makers, as well as to establish hierarchical quality standards of literatures in China. Scholars from university and teaching hospitals should cooperate with and benefit from each other.